Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 73, Issue 9

Altered intestinal and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated in atezolizumab/bevacizumab non-responders No Access

Abstract

Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide.

Monitoring of HCC and predicting its immunotherapy responses are challenging.

This study explored the potential of the gut microbiome for HCC monitoring and predicting HCC immunotherapy responses.

DNA samples were collected from the faeces of 22 patients with HCC treated with atezolizumab/bevacizumab (Atz/Bev) and 85 healthy controls. The gut microbiome was analysed using 16S rRNA next-generation sequencing and quantitative PCR (qPCR).

The microbiomes of patients with HCC demonstrated significant enrichment of , particularly , and , notably . Comparative analysis between Atz/Bev responders (R) and non-responders (NR) revealed a higher abundance of in the NR group and in the R group. Using qPCR analysis, we observed elevated levels of and reduced levels of 5α-reductase genes, essential for the synthesis of isoallolithocholic acid, in HCC patients compared to controls. Additionally, the analysis confirmed a significantly lower abundance of in the Atz/Bev R group relative to the NR group.

The gut microbiome analysis and specific gene quantification via qPCR could provide a rapid, less invasive, and cost-effective approach for assessing the increased risk of HCC, monitoring patient status, and predicting immunotherapy responses.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): 5α-reductase , atezolizumab-bevacizumab , Bacteroides stercoris , hepatocellular carcinoma and Streptococcus anginosus
Funding
This study was supported by the:
  • Japan Society for the Promotion of Science London (Award 23K11942)
    • Principal Award Recipient: TadashiFujii
© 2024 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001878
2024-09-06
2025-11-08

Metrics

Loading full text...

Full text loading...

References

  1. Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017; 14:527–539 [View Article] [PubMed]
     [Google Scholar]
  2. Das BK. Altered gut microbiota in hepatocellular carcinoma: insights into the pathogenic mechanism and preclinical to clinical findings. APMIS 2022; 130:719–740 [View Article] [PubMed]
     [Google Scholar]
  3. Lee KA, Luong MK, Shaw H, Nathan P, Bataille V et al. The gut microbiome: what the oncologist ought to know. Br J Cancer 2021; 125:1197–1209 [View Article] [PubMed]
     [Google Scholar]
  4. Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy. J Hepatol 2020; 72:230–238 [View Article] [PubMed]
     [Google Scholar]
  5. Jiang JW, Chen XH, Ren Z, Zheng SS. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int 2019; 18:19–27 [View Article] [PubMed]
     [Google Scholar]
  6. Fujii T, Nakano M, Shinohara H, Ishikawa H, Yasutake T et al. 1-kestose supplementation increases levels of a 5α-reductase gene, a key isoallolithocholic acid biosynthetic gene, in the intestinal microbiota. J Nutr Sci Vitaminol 2022; 68:446–451 [View Article] [PubMed]
     [Google Scholar]
  7. Fujii T, Nakagawa Y, Funasaka K, Hirooka Y, Tochio T. Levels of 5α-reductase gene in intestinal lavage fluid decrease with progression of colorectal cancer. J Med Microbiol 2024; 73:10 [View Article] [PubMed]
     [Google Scholar]
  8. Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology 2023; 77:1773–1796 [View Article] [PubMed]
     [Google Scholar]
  9. Kim TK, Herbst RS, Chen L. Defining and understanding adaptive resistance in cancer immunotherapy. Trends Immunol 2018; 39:624–631 [View Article] [PubMed]
     [Google Scholar]
  10. Gao X, Zhao R, Ma H, Zuo S. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis. BMC Cancer 2023; 23:635 [View Article] [PubMed]
     [Google Scholar]
  11. Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med 2019; 6:119 [View Article]
     [Google Scholar]
  12. Huang J, Zheng X, Kang W, Hao H, Mao Y et al. Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Front Immunol 2022; 13:874922 [View Article]
     [Google Scholar]
  13. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen W-S et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 2021; 27:1432–1441 [View Article] [PubMed]
     [Google Scholar]
  14. Mao J, Wang D, Long J, Yang X, Lin J et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer 2021; 9:e003334 [View Article] [PubMed]
     [Google Scholar]
  15. Hes C, Jagoe RT. Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle. BJC Rep 2023; 1:5 [View Article]
     [Google Scholar]
  16. Kuzuya T, Kawabe N, Hashimoto S, Miyahara R, Sawaki A et al. Early changes in alpha-fetoprotein are a useful predictor of efficacy of Atezolizumab plus Bevacizumab treatment in patients with advanced hepatocellular carcinoma. Oncology 2022; 100:12–21 [View Article] [PubMed]
     [Google Scholar]
  17. Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. Development of a prokaryotic universal primer for simultaneous analysis of Bacteria and Archaea using next-generation sequencing. PLoS One 2014; 9:e105592 [View Article] [PubMed]
     [Google Scholar]
  18. Hyun YJ, Lee JH, Kim DH. Cloning, overexpression, and characterization of recombinant heparinase III from Bacteroides stercoris HJ-15. Appl Microbiol Biotechnol 2010; 86:879–890 [View Article] [PubMed]
     [Google Scholar]
  19. Furet J-P, Firmesse O, Gourmelon M, Bridonneau C, Tap J et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol 2009; 68:351–362 [View Article] [PubMed]
     [Google Scholar]
  20. Yoon S-H, Ha S-M, Kwon S, Lim J, Kim Y et al. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int J Syst Evol Microbiol 2017; 67:1613–1617 [View Article] [PubMed]
     [Google Scholar]
  21. Lee JH, Kim HW, Mustafa B, Lee HI, Kwon HW. The relationships between microbiome diversity and epidemiology in domestic species of malaria-mediated mosquitoes of Korea. Sci Rep 2023; 13:9081 [View Article]
     [Google Scholar]
  22. Downes J, Vartoukian SR, Dewhirst FE, Izard J, Chen T et al. Pyramidobacter piscolens gen. nov., sp. nov., a member of the phylum “Synergistetes” isolated from the human oral cavity. Int J Syst Evol Microbiol 2009; 59:972–980 [View Article] [PubMed]
     [Google Scholar]
  23. Li ZP, Liu JX, Lu LL, Wang LL, Xu L et al. Overgrowth of lactobacillus in gastric cancer. World J Gastrointest Oncol 2021; 13:1099–1108 [View Article]
     [Google Scholar]
  24. Nagata N, Nishijima S, Kojima Y, Hisada Y, Imbe K et al. Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study. Gastroenterology 2022; 163:222–238 [View Article] [PubMed]
     [Google Scholar]
  25. Morita E, Narikiyo M, Yano A, Nishimura E, Igaki H et al. Different frequencies of Streptococcus anginosus infection in oral cancer and esophageal cancer. Cancer Sci 2003; 94:492–496 [View Article] [PubMed]
     [Google Scholar]
  26. Zhou C-B, Pan S-Y, Jin P, Deng J-W, Xue J-H et al. Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for noninvasive screening and early warning of gastric cancer. Gastroenterology 2022; 162:1933–1947 [View Article] [PubMed]
     [Google Scholar]
  27. Kuryłek A, Stasiak M, Kern-Zdanowicz I. Virulence factors of Streptococcus anginosus - a molecular perspective. Front Microbiol 2022; 13:1025136 [View Article] [PubMed]
     [Google Scholar]
  28. Crost EH, Tailford LE, Monestier M, Swarbreck D, Henrissat B et al. The mucin-degradation strategy of Ruminococcus gnavus: the importance of intramolecular trans-sialidases. Gut Microbes 2016; 7:302–312 [View Article] [PubMed]
     [Google Scholar]
  29. Song Y, Lau HC, Zhang X, Yu J. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma. Cancer Biol Med 2023; 21:144–162 [View Article] [PubMed]
     [Google Scholar]
  30. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995; 31A:1067–1070 [View Article] [PubMed]
     [Google Scholar]
  31. Sato Y, Atarashi K, Plichta DR, Arai Y, Sasajima S et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature 2021; 599:458–464 [View Article] [PubMed]
     [Google Scholar]
  32. Shiffka SJ, Kane MA, Swaan PW. Planar bile acids in health and disease. Biochim Biophys Acta Biomembr 2017; 1859:2269–2276 [View Article] [PubMed]
     [Google Scholar]
  33. Li W, Hang S, Fang Y, Bae S, Zhang Y et al. A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1. Cell Host Microbe 2021; 29:1366–1377 [View Article] [PubMed]
     [Google Scholar]
  34. Liu X, Mao B, Gu J, Wu J, Cui S et al. Blautia-a new functional genus with potential probiotic properties?. Gut Microbes 2021; 13:1–21 [View Article] [PubMed]
     [Google Scholar]
  35. Allen-Vercoe E, Daigneault M, White A, Panaccione R, Duncan SH et al. Anaerostipes hadrus comb. nov., a dominant species within the human colonic microbiota; reclassification of Eubacterium hadrum Moore et al. 1976. Anaerobe 2012; 18:523–529 [View Article]
     [Google Scholar]
  36. Nagpal R, Kurakawa T, Tsuji H, Takahashi T, Kawashima K et al. Evolution of gut Bifidobacterium population in healthy Japanese infants over the first three years of life: a quantitative assessment. Sci Rep 2017; 7:10097 [View Article] [PubMed]
     [Google Scholar]
  37. Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 2016; 7:979 [View Article] [PubMed]
     [Google Scholar]
  38. Gu M, Yin W, Zhang J, Yin J, Tang X et al. Role of gut microbiota and bacterial metabolites in mucins of colorectal cancer. Front Cell Infect Microbiol 2023; 13:1119992 [View Article] [PubMed]
     [Google Scholar]
  39. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461:1282–1286 [View Article] [PubMed]
     [Google Scholar]
  40. Skelly AN, Sato Y, Kearney S, Honda K. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat Rev Immunol 2019; 19:305–323 [View Article] [PubMed]
     [Google Scholar]
  41. Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism shapes the gut microbiota. Science 2018; 362:eaat9076 [View Article] [PubMed]
     [Google Scholar]
  42. Ueno M, Kosaka H, Iida H, Ida Y, Aoi K et al. Response prediction model of Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study. Oncology 2023; 101:565–574 [View Article] [PubMed]
     [Google Scholar]
  43. Wei F, Su Y, Quan Y, Li X, Zou Q et al. Anticoagulants enhance molecular and cellular immunotherapy of cancer by improving tumor microcirculation structure and function and redistributing tumor infiltrates. Clin Cancer Res 2023; 29:2525–2539 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001878
Loading
Altered intestinal Streptococcus anginosus and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab/bevacizumab non-responders
J. Med. Microbiol. 73, 001878 (2024); https://doi.org/10.1099/jmm.0.001878
/content/journal/jmm/10.1099/jmm.0.001878
/content/journal/jmm/10.1099/jmm.0.001878
Loading

Data & Media loading...

Supplements

Supplementary material 1

EXCEL

Supplementary material 2

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error